US biotech major Amgen (Nasdaq: AMGN) announced that it has reached resolution of its patent infringement litigation related to South Korea-based Celltrion’s (Kosdaq: 068270) denosumab biosimilar products, Amgen brands Prolia and Xgeva.
The court’s order issued on January 24, 2025, holds the claims of Amgen’s US patents asserted against Celltrion valid, enforceable and infringed by Celltrion's denosumab biosimilars in the USA.
In addition, Amgen and Celltrion have reached a confidential settlement that allows Celltrion to launch its biosimilar products in the U.S. as early as June 1, 2025. Specific financial terms remain confidential. The settlement and court decision affirm the strength of Amgen's patent rights for denosumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze